Pharmacokinetics of a parenteral carbapenem, biapenem, in patients with end-stage renal disease and influence of haemodialysis.
The effects of haemodialysis on the pharmacokinetics of a carbapenem, biapenem, were evaluated in five patients with end-stage renal disease, who received 1 h iv infusions of 300 mg biapenem on both the days on and off 4 h haemodialysis. With haemodialysis, plasma biapenem exhibited two elimination phases, one during and the other after haemodialysis with half-lives of 1.16 +/- 0.12 and 3.33 +/- 0. 91 h, respectively. Ninety percent of biapenem was removed from blood to dialysate. Without haemodialysis, plasma biapenem was mono-exponentially eliminated with a half-life of 4.35 +/- 1.30 h.
Nagashima
S
S
Department of Pharmacology, Gifu University School of Medicine, 40 Tsukasa-machi, Gifu 500-8705, Japan.
Kozawa
O
O
Otsuka
T
T
Kohno
K
K
Minamoto
M
M
Yokokawa
M
M
Kanamaru
M
M
Uematsu
T
T
D000328:Adult; D000890:Anti-Infective Agents / Q000097:blood* / Q000493:pharmacokinetics; D019540:Area Under Curve; D006207:Half-Life; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood*; D008875:Middle Aged; D006435:Renal Dialysis / Q000379:methods; D013845:Thienamycins / Q000097:blood* / Q000493:pharmacokinetics
D000890:Anti-Infective Agents; D013845:Thienamycins; C065257:biapenem